High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
about
Cancer diagnostic classifiers based on quantitative DNA methylationQuantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumorsValidation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.TGF-β mediated DNA methylation in prostate cancer.DNA methylation gene-based models indicating independent poor outcome in prostate cancer.Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate CancerChemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients.Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticityMethylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.DNA methylation changes in prostate cancer: current developments and future clinical implementation.Epigenetic regulation of prostate cancerEvaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.Pyrosequencing Analysis of APC Methylation Level in Human Prostate Tissues: A Molecular Marker for Prostate Cancer.Methylation of the RARB gene increases prostate cancer risk in black AmericansSelenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cellsMiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway.Promoter hypermethylation in prostate cancer.The epigenetic promise for prostate cancer diagnosis.Diagnostic and prognostic molecular biomarkers for prostate cancer.APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.Methylation markers for prostate cancer prognosis: a systematic review.Prostate cancer epigenetic biomarkers: next-generation technologies.Wnt signaling in castration-resistant prostate cancer: implications for therapy.Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer.Prognostic DNA methylation markers for prostate cancer.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a reviewThe epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.Diagnostic and prognostic epigenetic biomarkers in cancer.Molecular biomarkers to guide precision medicine in localized prostate cancer.Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.EMT and tumor metastasisDevelopment of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma.Molecular and physiological mechanisms of membrane receptor systems functioning.
P2860
Q27012960-AF5AEFF0-CD63-4F75-B882-06D3718C50ACQ28751911-2AF82FC0-4062-4DCD-AE2E-67AE97652736Q30582750-43B78A5F-09DE-496C-97D2-C07A2A06B0E8Q34039935-9D111229-DC10-4200-9180-4E4FFA055B28Q34174356-08921CC9-DC02-4DBB-921D-43BA39E4EEAEQ34324983-11B904CD-D815-4946-A515-AB41A28FB680Q34659119-29BD6869-EB2F-43FA-8368-5211E5C23F2EQ34680105-03E26BCE-A560-44E3-9103-BD2AECC62777Q34847101-57C0F255-7088-4642-8E48-C0C9F4171132Q35636543-A44B971C-B9FC-42C0-AD3C-6BBBA9B3D628Q36001910-7270A451-CD2F-4D35-B780-D355925A65D8Q36097736-6B83AFB1-EFFD-47E8-9259-24F32CCE7B9EQ36189798-EE2F61EE-BC41-4EA6-B5D1-9ED661B0D4FCQ36447329-8BD8EA61-5DD5-43E2-8981-F5DB4127A233Q36705589-254649E3-8D1D-4BAE-A411-6637096CBBB3Q37187963-0CC23087-4BE3-4E62-A124-A5A1D2BC079FQ37294669-1437CEF9-520B-47CF-869B-CDA1FD9D28B4Q37615759-4390AF4F-4FB5-44E0-8D74-8CC8BD67790DQ37688635-B582D850-7667-4FF7-8904-430172997155Q37791396-85566E87-8015-45E5-AB80-951BF86C40A0Q37967574-44DFB92F-CEDA-4FE6-89C4-4DE29A6600C7Q37972703-DF11C4A5-D70B-48F1-B862-E5812A765DE9Q38072660-7EE6126A-712D-4AC9-9E6D-B8072894EBD7Q38116745-79117660-0A5A-45D6-9AED-0BFE90353C53Q38212471-DA6FA170-0A07-4EC6-B2C9-3D29221355DEQ38241850-29D8B80A-B84B-4652-A475-C4BE5D5FD16BQ38242279-86ACFB86-7B2C-437B-B2E8-D9CCFAF82B14Q38252624-63AC2972-AEF9-40C3-A6BE-DEC895FA963CQ38253055-67A6932D-F8C7-4E70-9B1F-7BFAFC800E6EQ38269155-D93DB996-29F7-4925-85FD-F5F6A0031789Q38610743-E03176A9-6F74-4A04-AF84-4961C0B00275Q38668635-18A63B4F-6E65-48DA-BB39-6C3049731B3AQ38733030-62F56528-9EBF-40E5-A515-D3AE5DA2E8ECQ39216425-536FA92A-2E39-476C-B1CB-BA8BEA59573EQ40222443-987B522F-21C7-4B9A-AB14-A11997C3CAF5Q40454546-1596392E-BA1B-4786-BF1B-CDC04523FB1AQ40674443-FABEBB3B-11EF-4355-B002-1234C1189F63Q40920100-F27179A2-160C-45D7-ACE7-5FC6F017C186Q42102286-998B037A-1137-426A-A105-BB19F2633814Q42153161-F00D8140-9E80-4EFA-903C-1093ACFBAB61
P2860
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
High promoter methylation leve ...... from prostate cancer patients.
@en
High promoter methylation leve ...... from prostate cancer patients.
@nl
type
label
High promoter methylation leve ...... from prostate cancer patients.
@en
High promoter methylation leve ...... from prostate cancer patients.
@nl
prefLabel
High promoter methylation leve ...... from prostate cancer patients.
@en
High promoter methylation leve ...... from prostate cancer patients.
@nl
P2093
P50
P1476
High promoter methylation leve ...... from prostate cancer patients.
@en
P2093
Daniel Fonseca
David Sidransky
Franclim R Ribeiro
Jorge Oliveira
Vera L Costa
P304
P356
10.1158/1078-0432.CCR-07-1042
P407
P50
P577
2007-10-01T00:00:00Z